US GAO says FDA medical products oversight is "high risk"
This article was originally published in Scrip
The US FDA's oversight of drugs and medical devices is a "high risk area" in need of broad-based transformation to protect the public health, the US Government Accountability Office(GAO), Congress's investigative arm, says in a new report.
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher; Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.